PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

交易中 10-28 14:16:57 EDT

16.22

+0.01

+0.06%

最高16.27	最低16.07	成交量53.24万
今开16.20	昨收16.21	日振幅1.22%
总市值15.12亿	流通市值13.32亿	总股本9,325万
成交额861.61万	换手率0.65%	流通股本8,210万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":16.22,"timestamp":1761675411183,"preClose":16.21,"halted":0,"volume":532421,"delay":0,"floatShares":82100700,"shares":93246403,"eps":-0.157563,"marketStatus":"交易中","change":0.01,"latestTime":"10-28 14:16:57 EDT","open":16.195,"high":16.268,"low":16.07,"amount":8616094.50406,"amplitude":0.012215,"askPrice":16.23,"askSize":180,"bidPrice":16.22,"bidSize":286,"shortable":3,"etf":0,"ttmEps":-0.157563,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1761681600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":16.21,"preHourTrading":{"tag":"盘前","latestPrice":16.22,"preClose":16.21,"latestTime":"09:29 EDT","volume":400,"amount":6488.150000000001,"timestamp":1761658199999},"postHourTrading":{"tag":"盘后","latestPrice":16.21,"preClose":16.21,"latestTime":"19:17 EDT","volume":113415,"amount":1838456.99,"timestamp":1761607035343},"volumeRatio":0.322713,"impliedVol":0.5983,"impliedVolPercentile":0.612},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2577367573","title":"PD-(L)1/VEGF赛道攻坚，依沃西冲击首个海外适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367573","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577367573?lang=zh_cn&edition=full","pubTime":"2025-10-22 11:58","pubTimestamp":1761105514,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明当地时间10月20日，SummitTherapeutics（纳斯达克股票代码：SMMT）在2025年三季度财报中宣布，将于2025年第四季度向美国食品药品监督管理局（FDA）提交依沃西单抗联合化疗的生物制品许可申请（BLA），用于治疗经第三代EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌（NSCLC）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510223540978275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540978275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","BK4588","L","LU1169590202.USD","LU2487616109.SGD","PD","LU0210528500.USD","BK4585","LU0053666078.USD","BK4107","LU1169589451.USD"],"gpt_icon":0},{"id":"2577681314","title":"【券商聚焦】交银国际维持康方生物(09926)买入评级 指依沃西较PD-1显著提升一线肺鳞癌PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2577681314","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577681314?lang=zh_cn&edition=full","pubTime":"2025-10-21 09:06","pubTimestamp":1761008790,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 在ESMO大会上公布了HARMONi-6研究的首次PFS分析结果。关键亚组分析显示，依沃西在PD-L1低表达人群中显示长拖尾效应。非头对头比较显示，依沃西中位PFS数值明显好于其他PD-1单靶药物，且相较PD-1的PFS改善绝对值已超过PD-1相较传统化疗的改善程度。依沃西新适应症上市申请已于2025年7月获CDE受理。该机构认为，依沃西最新临床数据已再次验证其相对现有PD-1标准治疗的显著疗效优势，彰显其成长为下一代 I/O 基石产品的潜力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968146","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","PD","PFS"],"gpt_icon":0},{"id":"2576000514","title":"复宏汉霖PD-L1 ADC HLX43获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2576000514","media":"南方财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576000514?lang=zh_cn&edition=full","pubTime":"2025-10-20 08:47","pubTimestamp":1760921250,"startTime":"0","endTime":"0","summary":"南方财经10月20日电，复宏汉霖宣布，公司创新型程序性死亡-配体1（PD-L1）抗体偶联药物（ADC）注射用HLX43已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定（OrphanDrugDesignation,ODD），用于胸腺上皮肿瘤（ThymicEpithelialTumors，TETs）的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510203538123857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU1169590202.USD","PD","BK4080","BK4023","ADC","LU1169589451.USD","02696","BK4231"],"gpt_icon":0},{"id":"2575442735","title":"港股异动 | 基石药业-B(02616)涨超3% 将于ESMO大会上公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2575442735","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575442735?lang=zh_cn&edition=full","pubTime":"2025-10-13 09:40","pubTimestamp":1760319650,"startTime":"0","endTime":"0","summary":"消息面上，基石药业-B发布公告，2025年欧洲肿瘤内科学会年会即将于2025年10月17日至21日在德国柏林举行。基石药业核心临床管线CS2009进行中的 I期剂量递增临床数据摘要和CS5001进行中的Ib期临床研究设计摘要目前已在 ESMO官网公布。在即将正式召开的ESMO大会上，基石药业将以壁报形式展示CS2009在约70例晚期实体瘤患者中的I期剂量递增临床研究初步数据，这也将是目前已知全球首个关于PD-1/VEGF/CTLA-4三特异性抗体的临床数据发表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","PD","LU1169589451.USD","LU1169590202.USD","BK4023","YANG","02616","BK1574","BK4614"],"gpt_icon":1},{"id":"2575444962","title":"基石药业-B(02616)将公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据和ROR1 ADC最新研究设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2575444962","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575444962?lang=zh_cn&edition=full","pubTime":"2025-10-13 08:08","pubTimestamp":1760314120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，2025年欧洲肿瘤内科学会年会即将于2025年10月17日至21日在德国柏林举行。基石药业核心临床管线CS2009进行中的 I期剂量递增临床数据摘要和CS5001进行中的Ib期临床研究设计摘要目前已在 ESMO官网公布。在即将正式召开的ESMO大会上，基石药业将以壁报形式展示CS2009在约70例晚期实体瘤患者中的I期剂量递增临床研究初步数据，这也将是目前已知全球首个关于PD-1/VEGF/CTLA-4三特异性抗体的临床数据发表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4023","ADC","BK4080","BK1574","LU1169589451.USD","PD","02616","BK4231","LU1169590202.USD"],"gpt_icon":0},{"id":"2574133766","title":"山西证券：首予三生制药(01530)“买入-B”评级 PD-1/VEGF双抗是潜在的肿瘤基石药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2574133766","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574133766?lang=zh_cn&edition=full","pubTime":"2025-10-09 15:14","pubTimestamp":1759994066,"startTime":"0","endTime":"0","summary":"公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元，潜在里程碑付款48亿美元，以及双位数销售梯度分成。山西证券主要观点如下：SSGJ-707是潜在的肿瘤基石药物PD-1疗法是肿瘤治疗的基础方案之一，预计PD-1单抗全球市场在2029年达990亿美元。PD-1/VEGF双抗对抗血管和免疫检查点协同抑制，具比PD-1单抗更优的疗效潜力。SSGJ-707是四价结构的PD-1/VEGF双抗，VEGF存在下对PD-1结合亲和力增强100倍，独特的IgG4 Fc设计有望降低免疫副作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002500","01530","PD"],"gpt_icon":0},{"id":"2574187727","title":"天风证券：维持和誉-B(02256)“买入”评级 口服PD-L1与多药联用布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2574187727","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574187727?lang=zh_cn&edition=full","pubTime":"2025-10-09 14:09","pubTimestamp":1759990163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天风证券发布研报称，维持和誉-B“买入”评级，预计公司2025-2027年的营业收入分别为6.30亿元、6.85亿元和6.37亿元，归母净利润为0.45亿元、0.70亿元和1.02亿元。公司的PD-L1小分子抑制剂ABSK043联合KRASG12C抑制剂戈来雷塞片开展联合用药治疗KRASG12C突变的NSCLC的临床研究申请获CDE批准。此前，公司已经与艾力斯就联合用药达成了合作协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601162","02256","PD"],"gpt_icon":0},{"id":"2574903384","title":"Pagerduty, Inc.盘中异动 急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574903384","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574903384?lang=zh_cn&edition=full","pubTime":"2025-10-09 00:13","pubTimestamp":1759940032,"startTime":"0","endTime":"0","summary":"北京时间2025年10月09日00时13分，Pagerduty, Inc.股票出现异动，股价急速拉升5.05%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.41%。其相关个股中，Connexa Sports Technologies Inc.、Smith Micro Software, Inc.、Figma, Inc.涨幅较大，Connexa Sports Technologies Inc.、一品威客、Signing Day Sports, Inc.较为活跃，换手率分别为4837.41%、330.11%、46.66%，振幅较大的相关个股有Connexa Sports Technologies Inc.、一品威客、Triller Group Inc C/Wts 15/03/2027 ，振幅分别为126.00%、35.36%、33.96%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009001353a6b0ee03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","BK4023","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2569079058","title":"安克 9 月 27 日推出 45W 屏显充电头：可折叠插脚、有望支持 PD 3.2 AVS 协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2569079058","media":"IT之家","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569079058?lang=zh_cn&edition=full","pubTime":"2025-09-23 16:54","pubTimestamp":1758617698,"startTime":"0","endTime":"0","summary":"IT之家 9 月 23 日消息，安克在小红书发文，宣布将于 9 月 27 日推出一款 45W 屏显充电头，号称专为苹果 iPhone 17 系列手机打造，有望支持 PD3.2 AVS 协议。\n\n\n\n\n\n\n\n\n此前爆料显示，这款充电头型号为 A2693，整体体积约 4.3 x 3.6 x 3.5cm，采用可折叠插脚设计，正面配备一块隐藏式显示屏，同时支持安克 App 管理。","market":"us","thumbnail":"https://k.sinaimg.cn/n/spider20250923/90/w1440h1050/20250923/21b4-f7f6633d987180b766d4b737a2b3eb6c.jpg/w120h90l50t18f7.jpg","type":0,"news_type":0,"thumbnails":["https://k.sinaimg.cn/n/spider20250923/90/w1440h1050/20250923/21b4-f7f6633d987180b766d4b737a2b3eb6c.jpg/w120h90l50t18f7.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.sina.cn/mobile/xp/2025-09-23/detail-infrnqym2562448.d.html?vt=4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_tech","symbols":["AVS","LU1169590202.USD","PD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2569759936","title":"基石药业-B(02616)：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验于澳大利亚完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2569759936","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569759936?lang=zh_cn&edition=full","pubTime":"2025-09-23 08:04","pubTimestamp":1758585872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司核心管线CS2009的全球多中心II期临床试验于澳大利亚完成首例患者入组。该试验目前正在澳大利亚和中国积极入组，未来将扩展至美国。CS2009是基石药业从分子设计开始自主研发的一款靶向PD-1、VEGFA和CTLA-4的新型三特异性抗体，通过协同作用实现多维度的抗肿瘤效应，具备同类首创/同类最佳潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU1169590202.USD","LU1169589451.USD","BK1161","02616","BK4023","BK1574"],"gpt_icon":0},{"id":"2568547826","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)用于治疗晚期非小细胞肺癌的国际多中心2期临床研究完成澳大利亚首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2568547826","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568547826?lang=zh_cn&edition=full","pubTime":"2025-09-18 17:33","pubTimestamp":1758188018,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，一项注射用HLX43在晚期非小细胞肺癌患者中开展的国际多中心2期临床研究已完成澳大利亚首例患者给药。2025年9月，HLX43的1期临床更新数据于2025年世界肺癌大会大会上发布。HLX43为靶向PD-L1的抗体偶联药物。截至本公告日，于全球范围内尚无靶向PD-L1的抗体偶联药物获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK1161","PD","02696","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2567159366","title":"苹果发布40W动态电源适配器 支持PD 60W峰值充电","url":"https://stock-news.laohu8.com/highlight/detail?id=2567159366","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567159366?lang=zh_cn&edition=full","pubTime":"2025-09-14 20:34","pubTimestamp":1757853242,"startTime":"0","endTime":"0","summary":"苹果在2025年秋季新品发布会后推出新款充电头“40W 动态电源适配器”，该充电头支持 USB PD 3.2 AVS 技术，可根据设备需求动态调节输出功率，国行定价为329元。有海外用户使用 USB 充电测试工具进行协议测试，发现测试工具仅检测到该充电头支持 USB PD 40W 功率。测试用户表示，这款充电头可以与普通 USB PD 60W 设备向下兼容，即使用户设备不支持最新的 PD 3.2 技术，只要设备本身支持最高 60W PD 输入，即可获得 60W 峰值充电速度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250914203808a7207356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065170008.USD","LU1066053197.SGD","LU0170899867.USD","LU0965508806.USD","IE00BJTD4N35.SGD","LU1934455277.USD","LU0494093205.USD","LU1582987597.SGD","LU2360032135.SGD","BK4579","LU2237443622.USD","BK4598","LU0466842654.USD","IE00B19Z8X17.USD","LU0082616367.USD","LU0320765059.SGD","LU0689626769.HKD","BK4571","MACW.SI","SGXZ31699556.SGD","LU0726765562.USD","LU0256863902.USD","LU0069063385.USD","PD","LU1868836757.USD","IE00BFSS8Q28.SGD","IE00BZ1G4Q59.USD","IE00B19Z9505.USD","SG9999014567.USD","LU1003077747.HKD","GB00BDT5M118.USD","LU1989772840.SGD","LU2106854487.HKD","LU0553294199.USD","LU0265550359.USD","LU1989764664.SGD","BK4554","BK4576","LU2471134952.CNY","LU1674673428.USD","LU0823434740.USD","BK4574","AAPL","LU0965509101.SGD","LU1066051225.USD","LU2360106780.USD","LU2250418816.HKD","LU0957808578.USD","LU0077335932.USD","LU2430703178.SGD"],"gpt_icon":0},{"id":"2565507127","title":"复宏汉霖(02696)：帕博利珠单抗生物类似药HLX17(重组抗PD-1人源化单克隆抗体注射液)在多种已切除实体瘤患者中的临床试验申请获美国食品药品管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2565507127","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565507127?lang=zh_cn&edition=full","pubTime":"2025-09-08 17:44","pubTimestamp":1757324660,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696)发布公告，近日，公司自主研发的帕博利珠单抗生物类似药HLX1...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_6.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1342664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4023","02696","BK1161","PD","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2565526301","title":"9月7日康方生物依沃西单抗（AK112）首个全球多中心Ⅲ期临床研究HARMONi的更新数据在世界肺癌大会上公布。该研究评","url":"https://stock-news.laohu8.com/highlight/detail?id=2565526301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565526301?lang=zh_cn&edition=full","pubTime":"2025-09-07 22:03","pubTimestamp":1757253791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1291159041.SGD","SG9999002232.USD","LU0098860793.USD","MRK","SG9999014542.SGD","SG9999001440.SGD","LU1162221912.USD","PD","LU0208291251.USD","LU0965509101.SGD","LU1720050803.USD","LU0006306889.USD","LU0289739699.SGD","LU0348783233.USD","LU0211331839.USD","LU1116320901.HKD","LU1430594728.SGD","SG9999014559.SGD","IE0002141913.USD","LU0266013472.USD","LU0417516902.SGD","LU1983299246.USD","SG9999013999.USD","SG9999014575.USD","PFS","IE00BBT3K403.USD","09926","LU2461242641.AUD","LU0634319403.HKD","LU1023059063.AUD","LU1934455277.USD","SGXZ57979304.SGD","IE0009355771.USD","LU0417516738.SGD","LU0265550359.USD","LU0320765646.SGD","LU0348825331.USD","SG9999015358.SGD","LU1169590202.USD","LU0348767384.USD","LU1093756168.USD","LU1794554557.SGD","LU0265550946.USD","LU0238689110.USD","LU2324357040.USD","LU1069347547.HKD","LU0540923850.HKD","SG9999001176.SGD","LU1093756325.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2565587499","title":"港股异动 | 和誉-B(02256)高开逾6%破顶 公司近期迎多重利好 口服PD-L1联用戈来雷塞获批二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2565587499","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565587499?lang=zh_cn&edition=full","pubTime":"2025-09-05 09:30","pubTimestamp":1757035839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B高开逾6%，高见18.92港元创历史新高。消息面上，和誉近日宣布，在研口服PD-L1 抑制剂ABSK043 和艾力斯的KRAS G12C抑制剂戈来雷塞片联用治疗KRAS G12C突变的NSCLC的IND申请在中国获得批准。今年3月，公司和艾力斯就ABSK043达成合作协议，此次获批的是评估ABSK043和艾力斯的KRAS G12C抑制剂戈来雷塞片联用治疗KRASG12C突变的NSCLC的二期临床试验。8月27日公司回购20万股，8月28日又回购10万股。截至2025年6月30日，已累计回购954.5万股，合计7530万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2488822045.USD","LU1169589451.USD","LU1169590202.USD","PD","BK1161","BK4023"],"gpt_icon":0},{"id":"2565914304","title":"PagerDuty's H2 Outlook Buoyed by Pricing Moves Despite User Reductions, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2565914304","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565914304?lang=zh_cn&edition=full","pubTime":"2025-09-05 02:14","pubTimestamp":1757009671,"startTime":"0","endTime":"0","summary":"PagerDuty  reported mixed fiscal Q2 results and guidance as businesses reduced user licenses and tightened technology budgets, RBC Capital Markets said Thursday in a report.Despite ongoing reductions in user volume, management sees improved performance and pricing changes as catalysts for H2 acceleration, RBC said.\"While we remain cautious on seat-based headwinds, we are encouraged by the pricing moves,\" RBC said.The company's appointment of Todd McNabb as chief revenue officer is expected to strengthen the go-to-market strategy in the medium term, the report said.RBC reduced its price target on PagerDuty stock to $18 from $20 on lower estimates and maintained its outperform rating.PagerDuty shares rose 5.6% in recent Thursday trading.Price: 16.47, Change: +0.88, Percent Change: +5.64","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"加拿大皇家银行表示，尽管用户减少，但PagerDuty的下半年前景仍受到定价变动的提振","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PD","LU1169590202.USD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"1138284622","title":"异动解读 | 分析师上调目标价，PagerDuty盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284622","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138284622?lang=zh_cn&edition=full","pubTime":"2025-09-04 22:52","pubTimestamp":1756997543,"startTime":"0","endTime":"0","summary":"PagerDuty今日盘中大涨5%，引起投资者关注。据报道，多家券商对PagerDuty的投资评级和目标价进行了调整。尽管目标价有所下调，但分析师们仍然看好PagerDuty的长期发展前景。这些分析师评级的调整反映了市场对PagerDuty业务发展的持续关注。作为一家提供数字运营管理解决方案的公司，PagerDuty在当前数字化转型加速的背景下，其服务需求有望持续增长。投资者对公司未来的盈利能力保持乐观态度，推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"2564607303","title":"药捷安康-B(02617)：替恩戈替尼联用康方生物开坦尼®(卡度尼利，PD-1/CTLA-4)╱ 依达方®(依沃西，PD-1/VEGF)的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2564607303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564607303?lang=zh_cn&edition=full","pubTime":"2025-09-04 22:38","pubTimestamp":1756996699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司核心产品替恩戈替尼分别联用康方生物科技(开曼)有限公司开坦尼╱依达方的治疗晚期肝细胞癌的开放性、多中心II期临床研究，于近日完成首例患者给药。该试验的主要目标人群为既往未接受过针对肝细胞癌的全身抗肿瘤治疗或既往标准治疗失败后的晚期肝细胞癌患者。药捷安康已与康方生物订立合作协议，双方共同针对肝细胞癌领域开展临床联合用药开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","LU0348825331.USD","LU0634319403.HKD","LU0348827113.USD","LU0348766576.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","PD","LU2488822045.USD","LU2476274720.SGD","LU1720050803.USD","LU0417516902.SGD","LU1169590202.USD","LU2476274308.USD","LU2778985437.USD","02617","IE00BPRC5H50.USD","IE00B543WZ88.USD","BK1574","LU0348767384.USD","LU0561508036.HKD","LU0540923850.HKD","BK1161","LU1794554557.SGD","LU0348735423.USD","BK4023","LU0348784397.USD","LU0417516571.SGD"],"gpt_icon":1},{"id":"2564742713","title":"RBC Capital Adjusts PagerDuty Price Target to $18 From $20, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564742713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564742713?lang=zh_cn&edition=full","pubTime":"2025-09-04 20:30","pubTimestamp":1756989030,"startTime":"0","endTime":"0","summary":"PagerDuty (PD) has an average rating of overweight and mean price target of $18.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"RBC Capital将PagerDuty目标价从20美元调整至18美元，维持跑赢大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PD"],"gpt_icon":0},{"id":"2564325557","title":"招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564325557?lang=zh_cn&edition=full","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09887","ADC","PD","LU1169589451.USD","BK4080","ADC.AU","BK7095","BK4023","LU1169590202.USD","BK4231"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.024},{"period":"1month","weight":0.005},{"period":"3month","weight":-0.0122},{"period":"6month","weight":0.0451},{"period":"1year","weight":-0.0974},{"period":"ytd","weight":-0.1123}],"compareEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.0787},{"period":"6month","weight":0.2357},{"period":"1year","weight":0.1834},{"period":"ytd","weight":0.1692}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.045759},{"month":2,"riseRate":0.5,"avgChangeRate":-0.032478},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018297},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.049825},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.007313},{"month":6,"riseRate":0.714286,"avgChangeRate":0.021791},{"month":7,"riseRate":0.571429,"avgChangeRate":0.017838},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.000522},{"month":9,"riseRate":0,"avgChangeRate":-0.114196},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.035125},{"month":11,"riseRate":0.666667,"avgChangeRate":0.066825},{"month":12,"riseRate":0.5,"avgChangeRate":0.034253}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.4","shortVersion":"4.35.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}